Home institution: University of Basel
Antibiotics are powerful and indispensable drugs that not only treat life-threatening bacterial infections, but also protect patients with weakened immune systems who need medical treatment. However, the proportion of pathogenic bacteria that are resistant to one or more antibiotics is constantly increasing. The National Centre of Competence in Research "New approaches to combat antibiotic-resistant bacteria" (NCCR AntiResist) aims to fight the rapid global increase and spread of antibiotic resistance by facilitating the development of new anti-infectious strategies. To this end, the NCCR AntiResist seeks to revitalise antibiotic discovery through a patient-centered paradigm shift involving experts from various scientific fields such as clinical research, infection biology, chemistry, information technology, engineering and pharmacology. Research focusing on specific pathogens in the NCCR is conducted in four modules, each assessing one bacterium: Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus and Brucella melitensis.
Financing 2020 – 2023 (Swiss Francs):
Time-frame Funding source 2020 – 2023 SNSF grant 17'000’000 Funds of Basel University: 11’400’000 Group funds of the project participants: 2’135’383 External funds: 28'000’000 Total: 31’138’383
NCCRs are financed through grants awarded by the SNSF, but also from other sources. The home institution involved in the NCCR also contributes a substantial amount of money. The available overall budget of the NCCR is further increased by monetary contributions from the project participants and third-party funds, which are generally invested by industrial companies.